Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Shulman

Showing results (391-400 of 422) with videos related to

Pageof 43
Sort By:
Journal of Hepatology|October 18, 2015
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJordan J Feld, Christophe Moreno, Roger Trinh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 13, 2014
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4Gregory Everson, Curtis Cooper, Christophe Hézode, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 13, 2014
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR studyEdward J Gane, Paul J Pockros, Stefan Zeuzem, et al.
Journal of Viral Hepatitis|November 20, 2018
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infectionJacinta A Holmes, Charles Carlton-Smith, Arthur Y Kim, et al.
Journal of the National Cancer Institute|June 26, 2024
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group reportLenka Ilcisin, Ruxu Han, Mark Krailo, et al.
Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.
Annals of Internal Medicine|July 1, 1973
Cholestyramine in type II hyperlipoproteinemia. A double-blind trialR I Levy, D S Fredrickson, N J Stone, et al.
JCO Precision Oncology|May 14, 2026
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN StudyHolly J Roberts, Hannah Comeau, Kelly Klega, et al.
Journal of Clinical Medicine|April 30, 2021
Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future PerspectivesStefan K Zöllner, James F Amatruda, Sebastian Bauer, et al.
Cancer Medicine|March 22, 2021
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncologyDavid S Shulman, Lulla V Kiwinda, Stacey Edwards, et al.
Pageof 43

Showing results (391-400 of 422) with videos related to

Sort By:
Pageof 43
Journal of Hepatology|October 18, 2015
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJordan J Feld, Christophe Moreno, Roger Trinh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 13, 2014
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4Gregory Everson, Curtis Cooper, Christophe Hézode, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 13, 2014
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR studyEdward J Gane, Paul J Pockros, Stefan Zeuzem, et al.
Journal of Viral Hepatitis|November 20, 2018
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infectionJacinta A Holmes, Charles Carlton-Smith, Arthur Y Kim, et al.
Journal of the National Cancer Institute|June 26, 2024
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group reportLenka Ilcisin, Ruxu Han, Mark Krailo, et al.
Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.
Annals of Internal Medicine|July 1, 1973
Cholestyramine in type II hyperlipoproteinemia. A double-blind trialR I Levy, D S Fredrickson, N J Stone, et al.
JCO Precision Oncology|May 14, 2026
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN StudyHolly J Roberts, Hannah Comeau, Kelly Klega, et al.
Journal of Clinical Medicine|April 30, 2021
Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future PerspectivesStefan K Zöllner, James F Amatruda, Sebastian Bauer, et al.
Cancer Medicine|March 22, 2021
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncologyDavid S Shulman, Lulla V Kiwinda, Stacey Edwards, et al.
Pageof 43